Released Aug 15, 2022, before the open
10-Q filed Aug 15, 2022, 46 days after period end · 0001558370-22-013560
Q2 2022 · 10-Q
Revenue$8.75M$8.75M +36.2% vs Q2 2021−45.6% vs Q1 2022
Net Income-$5.33M-$5.33M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.11-$0.11 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$5,524,000N/M
Operating Cash Flowderived-$7,356,000N/M
Free Cash Flowderived-$7,484,000N/M
Margins · derived
Operating margin-63.1%+79.5 pt vs Q2 2021
Net margin-60.9%+114.0 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $8.75M | $6.43M | $10.97M | $12.25M |
| Net Income | -$5.33M | -$11.24M | -$4.15M | -$7.74M |
| EPS Diluted | -$0.11 | -$0.25 | -$0.13 | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR